Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management.

Armstrong MJ, Hazlehurst JM, Parker R, Koushiappi E, Mann J, Khan S, Philips A, Chandler L, Johnson J, Round M, Haydon G, Karamat MA, Newsome PN, Tomlinson JW.

QJM. 2014 Jan;107(1):33-41. doi: 10.1093/qjmed/hct198. Epub 2013 Oct 15.

2.

A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.

Chan WK, Nik Mustapha NR, Mahadeva S.

Hepatol Int. 2015 Oct;9(4):594-602. doi: 10.1007/s12072-014-9596-7. Epub 2014 Dec 6.

PMID:
25788185
3.

Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.

Sobhonslidsuk A, Pulsombat A, Kaewdoung P, Petraksa S.

Asian Pac J Cancer Prev. 2015;16(5):1789-94.

4.

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.

McPherson S, Stewart SF, Henderson E, Burt AD, Day CP.

Gut. 2010 Sep;59(9):1265-9. doi: 10.1136/gut.2010.216077.

PMID:
20801772
5.

NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.

Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD.

World J Gastroenterol. 2013 Feb 28;19(8):1219-29. doi: 10.3748/wjg.v19.i8.1219.

6.

An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes.

Williams KH, Burns K, Constantino M, Shackel NA, Prakoso E, Wong J, Wu T, George J, McCaughan GW, Twigg SM.

J Diabetes Complications. 2015 Nov-Dec;29(8):1240-7. doi: 10.1016/j.jdiacomp.2015.06.015. Epub 2015 Jul 3.

PMID:
26297218
7.

Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.

Williams KH, Viera de Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Bu Y, Brooks B, Cavanagh E, Raleigh J, McLennan SV, McCaughan GW, Bachovchin WW, Keane FM, Zekry A, Twigg SM, Gorrell MD.

Diabetes Res Clin Pract. 2015 Jun;108(3):466-72. doi: 10.1016/j.diabres.2015.02.024. Epub 2015 Mar 11.

PMID:
25836944
8.

Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.

Tapper EB, Sengupta N, Hunink MG, Afdhal NH, Lai M.

Am J Gastroenterol. 2015 Sep;110(9):1298-304. doi: 10.1038/ajg.2015.241. Epub 2015 Aug 25. Erratum in: Am J Gastroenterol. 2016 Mar;111(3):446.

PMID:
26303130
9.

Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography.

Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Woo J, Chan FK, Chan HL.

Gut. 2012 Mar;61(3):409-15. doi: 10.1136/gutjnl-2011-300342. Epub 2011 Aug 16.

PMID:
21846782
10.

Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.

Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, Gill PS, Neuberger JM, Lilford RJ, Newsome PN.

J Hepatol. 2012 Jan;56(1):234-40. doi: 10.1016/j.jhep.2011.03.020. Epub 2011 May 18.

11.

Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.

Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, Loomba R.

Aliment Pharmacol Ther. 2012 Jul;36(1):22-9. doi: 10.1111/j.1365-2036.2012.05121.x. Epub 2012 May 3.

12.

Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?

McPherson S, Anstee QM, Henderson E, Day CP, Burt AD.

Eur J Gastroenterol Hepatol. 2013 Jun;25(6):652-8. doi: 10.1097/MEG.0b013e32835d72cf.

PMID:
23325287
13.

Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.

Tapper EB, Hunink MG, Afdhal NH, Lai M, Sengupta N.

PLoS One. 2016 Feb 23;11(2):e0147237. doi: 10.1371/journal.pone.0147237. eCollection 2016.

14.

The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease.

Cichoż-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T.

Med Sci Monit. 2012 Dec;18(12):CR735-40.

15.

A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease.

Aykut UE, Akyuz U, Yesil A, Eren F, Gerin F, Ergelen R, Celikel CA, Yilmaz Y.

Scand J Gastroenterol. 2014 Nov;49(11):1343-8. doi: 10.3109/00365521.2014.958099. Epub 2014 Sep 26.

PMID:
25259621
16.

The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic.

Dvorak K, Hainer R, Petrtyl J, Zeman M, Vareka T, Zak A, Sroubkova R, Svestka T, Vitek L, Bruha R.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):442-8. doi: 10.5507/bp.2014.033. Epub 2014 Jun 25.

17.

Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.

Xun YH, Guo JC, Lou GQ, Jiang YM, Zhuang ZJ, Zhu MF, Luo Y, Ma XJ, Liu J, Bian DX, Shi JP.

Clin Exp Pharmacol Physiol. 2014 Sep;41(9):643-9. doi: 10.1111/1440-1681.12260.

PMID:
24837195
18.

Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD).

Raszeja-Wyszomirska J, Szymanik B, Ławniczak M, Kajor M, Chwist A, Milkiewicz P, Hartleb M.

BMC Gastroenterol. 2010 Jun 28;10:67. doi: 10.1186/1471-230X-10-67.

19.

Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.

Williams KH, Vieira De Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Brooks B, Bu Y, Cavanagh E, Raleigh J, McLennan SV, McCaughan GW, Keane FM, Zekry A, Gorrell MD, Twigg SM.

J Diabetes. 2015 Nov;7(6):809-19. doi: 10.1111/1753-0407.12237. Epub 2014 Dec 22.

PMID:
25350950
20.

Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease.

Alkhouri N, Sedki E, Alisi A, Lopez R, Pinzani M, Feldstein AE, Nobili V.

Liver Int. 2013 Jan;33(1):79-85. doi: 10.1111/liv.12024. Epub 2012 Nov 12.

PMID:
23146095

Supplemental Content

Support Center